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ABSTRACT 
 
6-Mercaptopurine is a chemotherapeutic agent of the antimetabolite class. This study aims to analyze 
simultaneous validation of 6-mercaptopurine (6-MP), 6-methylmercaptopurine (6-MMP), and 6-thioguanosine-5’-
monophosphate (6-TGMP) in dried blood spot (DBS) using ultra performance liquid chromatography-tandem mass 
spectrometry (UPLC-MS/MS). An accurate volume of 60 μL blood was spotted onto DBS-CAMAG paper and then 
extracted using methanol 90% (v/v) containing an internal standard of 5-fluorouracil (5-FU). Separation was 
performed using a Waters Acquity UPLC BEH AMIDA column 1.7 μm (2.1 x 100 mm) with a mobile phase mixture of 
0.2% (v/v) formic acid in water−0.1% (v/v) formic acid in acetonitrile-methanol with gradient elution and flow rate of 
0.2 mL/min. Mass detection was done using Waters Xevo TQD with positive electrospray ionization (ESI) for 6-MP, 
6-MMP, 6-TGMP and negative ESI for 5-FU, in multiple reaction monitoring mode. Detection rates of 6-MP, 6-MMP, 
6-TGMP and 5-FU were m/z 153.09 > 119.09; 167.17 > 126.03; 380.16 > 168.00); 129.09 > 42.05, respectively. This 
method is linear across the range of 25.5–1020 ng/mL for 6-MP, 6-MMP and 6-TGMP. This method is valid for the in 
vitro simultaneous analysis of 6-MP, 6-MMP and 6-TGMP in DBS, based on European Medicine Agency guidelines. 
 
Keywords: 6-mercaptopurine; dried blood spot; simultaneous analysis; method validation 
 
ABSTRAK 
 
6-Merkaptopurin merupakan agen kemoterapi yang termasuk golongan antimetabolit analog purin. Penelitian 
ini bertujuan untuk menganalisis secara simultan 6-merkaptopurin (6-MP),6-metilmerkaptopurin (6-MMP), dan 6-
tioguanosin-5'-monofosfat (6-TGMP) pada sampel darah kering dengan menggunakan kromatografi cair kinerja ultra 
tinggi-tandem spektrometri massa (KCKUT-SM/SM). Sebanyak 60 μL darah utuh ditotolkan pada kertas DBS-
CAMAG, ditambahkan baku dalam 5-fluorourasil (5-FU) kemudian diekstraksi menggunakan metanol 90% (v/v). 
Analisis dilakukan dengan kolom Waters Acquity UPLC BEH AMIDA 1,7 μm (2,1 x 100 mm) dengan fase gerak 
campuran 0,2% (v/v) asam format dalam air−0,1% (v/v) asam format dalam asetonitril-metanol, elusi secara gradien 
dan laju alir 0,2 mL/menit. Deteksi massa dilakukan menggunakan Waters Xevo TQD dengan ionisasi electrospray 
(ESI) positif untuk 6-MP, 6-MMP, 6-TGMP dan ESI negatif untuk 5-FU dengan mode multiple reaction monitoring. 
Deteksi 6-MP, 6-MMP, 6-TGMP, 5-FU masing-masing adalah m/z 153,09 > 119,09; 167,17 > 126,03; 380,16 > 
168,00); 129,09 > 42,05. Metode ini linier dengan kisaran 25,5–1020 ng/mL untuk 6 MP, 6-MMP, dan 6-TGMP. 
Metode ini valid untuk analisis 6-MP, 6-MMP, dan 6-TGMP pada sampel darah kering secara simultan secara in 
vitro sesuai dengan pedoman European Medicines Agency.  
 
Kata Kunci: 6-merkaptopurin; sampel darah kering; analisis simultan; validasi metode 
 
INTRODUCTION 
 
The chemotherapeutic agent of 6-mercaptopurine 
(6-MP) is used in most treatment protocols for acute 
lymphoblastic leukemia (ALL) [1-2]. 6-MP has three 
major metabolic pathways: the first uses the enzyme 
hypoxanthine-guanine phosphoribosyltransferase (HGPRT) 
to form its active metabolite, 6-thioguanine nucleotide 
(6-TGN). The second pathway uses the enzyme 
thiopurine methyltransferase (TPMT) to form 6-
methylmercaptopurine (6-MMP), and the third pathway 
uses the enzyme xanthine dehydrogenase to form 6-
thiouric acid [3-5]. In chemotherapy, the focus of 
clinical research is slowly shifting from improving 
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survival rates to decreasing chemotherapy-related 
adverse effects [6-7]. 6-MP produces a range of possible 
adverse drug reactions and a narrow therapeutic index; 
hence, the therapeutic index for each individual needs to 
be monitored [8]. 6-MP drug monitoring is usually 
performed by venipuncture [3,6,9-10]. Venous blood 
sampling has the disadvantages of requiring large blood 
samples, and as an invasive process, requiring medical 
personnel to perform venipuncture [11]. DBS analysis, 
which is a bio-sampling method developed recently for 
therapeutic drug monitoring, overcomes these problems. 
The main benefits of DBS analysis are the opportunity 
for long storage at room temperature, simple 
transportation in envelopes and minimally invasive blood 
sampling without direct sample processing. Due to this 
low processing burden, DBS analysis methods are 
particularly suitable for the elderly, children and infants 
for whom venipuncture is problematic [12-15]. 
This research aims to develop valid analytical 
methods for 6-MP, 6-MMP, and 6-TGMP simultaneously 
in DBS samples using UPLC-MS/MS with 5-fluorouracil 
as the internal standard. Sample preparation and 
extraction uses a mixture of aqueous, acetonitrile and 
methanol processes. Optimization and validation method 
meet the requirements of the European Medicine 
Agency. The new contribution of this research is to 
describe a simple, rapid, sensitive and selective method 
for simultaneous analysis of 6-mercaptopurine and its 
metabolites in DBS samples using UPLC-MS/MS. This 
method is still under development in the laboratory, and 
in future is expected to be applied in 6-MP therapeutic 
drug monitoring of childhood patients with ALL. 
 
EXPERIMENTAL SECTION 
 
Materials 
 
Acetonitrile HPLC grade (Merck), formic acid 
(Merck), methanol HPLC grade (Merck), 6-
mercaptopurine (Sigma-Aldrich), 6-methylmercaptopurine 
(Sigma-Aldrich), 6-thioguanosine-5’-monophosphate 
(Jena Bioscience) were used in this research. All water 
used was HPLC grade and prepared using a Millipore 
Direct-QTM 5 water system (Millipore, Watford, UK). 
Whole blood was obtained from the Indonesian Red 
Cross. 
 
Instrumentation 
 
The instruments used in this study were: 
quaternary solvent manager (Acquity UPLC H-Class), 
sample manager (Acquity UPLC), mass analyzer triple 
quadrupole (Xevo TQD), nitrogen generator compressor 
(PEAK Scientific), UPLC bridged ethylene hybrid AMIDA 
column 1.7 μm (2.1 mm × 100 mm), digital balance 
(AND), ultrasonic (Elmasonic S40H), deep freezer -20 
°C (Modena), TurboVap evaporator (Califer), vortex 
(Maxi Mix II), micropipettes (Soccorex) and millipore 
0.22 μm (Chrom Tech). 
 
Procedure 
 
Stock solutions, standards and quality controls 
Standard and stock solutions of 1 mg/mL of 
dissolved 6-MP, 6-MMP, 6-TGMP and 5-FU were 
freshly prepared, and the stock solutions were stored at 
-20 °C. All working standard solutions were freshly 
prepared from the stock before each analytic run. 
Calibrating solutions were freshly prepared at 
scalar concentrations by diluting stock solutions in 
acetonitrile 50% (v/v) for 6-MP, 6-MMP and 5-FU. The 
stock solution for 6-TGMP was diluted in water. These 
solutions would later be diluted in whole blood to 
produce the desired concentrations. 
 
DBS sample preparation 
Whole blood was obtained from the Indonesian 
Red Cross and stored at -40 °C until required. An 
aliquot of 60 µL blood standards of analytes was 
pipetted and spotted onto CAMAG DBS paper and 
dried for a minimum of 3 h at room temperature. The 
DBS samples were then cut and put into tubes. 
Extraction solution consisting of 1 mL methanol 90% 
(v/v) with the addition of 100 µL of internal standard of 
5-FU solution was added to the tubes. Tubes were 
sonicated for 25 min at 50 °C. The supernatant was 
then transferred into test tubes and evaporated with 
nitrogen for 25 min at 40 °C. It was then reconstituted 
in 100 µL acetonitrile 10% (v/v), then vortexed and 
sonicated for 10 sec. After being centrifuged at 3000 
rpm for 10 min with 10 µL of the aliquot, it was injected 
into the chromatographic system. 
 
Method validation 
Assay validation was performed based on the 
EMA guidelines for validation of bioanalytical assay 
[15-16]. In addition, experiments were conducted to 
determine the effects of DBS analysis on the 
selectivity, carry-over, lower limit of quantitation, 
calibration curve, accuracy, precision, dilution integrity, 
matrix effect and stability of the method. 
 
RESULT AND DISCUSSION 
 
Method Optimization 
 
The mobile phases used were 0.2% (v/v) formic 
acid in water−0.1% (v/v) formic acid in acetonitrile-
methanol. The flow rate was 0.2 mL/min using gradient 
elution conditions and injection volume of 5 µL. The 
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runtime was approximately 5 min. The mass selective 
detector was operated in electrospray ionization positive 
mode for analytes, and negative mode for the internal 
standard (IS). Mass spectrometric (MS) detection was 
performed using Waters Xevo TQD Triple Quadruple 
and multiple reaction monitoring was employed with 
mass resolutions of wide for MS1 and widest for MS2. 
High purity nitrogen was used as source and collision 
gas. Capillary voltage was set to 3.5 kV, 450 °C as the 
desolvation temperature, 700 L/h as desolvation gas 
flow and 0.025 msec as dwell time. 
The UPLC-MS/MS conditions to determine 
analytes and IS are shown in Table 1. Two product ions 
from one precursor ion were set for multiple reaction 
monitoring (MRM) mode. Typical chromatograms of the 
analytes (1.0 μg/mL) are shown in Fig. 1. 
Even when the MS/MS parameters are optimized 
for these product ions, their abundance remains low, as 
the majority of the precursor ions remain intact. 
Increasing the collisions further does not increase the 
abundance of these two product ions. However, the 
results show the formation of numerous lower-mass 
and low-abundance product ions [17-18]. 
 
Determination of Extraction Solvent 
 
Many smaller molecule methods use organic 
solvents to extract the analyte from the DBS sample. 
Organic solvents are generally used as extraction 
solutions because, in addition to being able to attract 
the analytes, organic solvents can precipitate blood 
proteins [19]. The addition of an organic solution to a 
solution of a protein in water can lower the dielectric 
constant of the solvent/water, thereby increasing the 
pull between the charged molecules and facilitating the 
electrostatic interaction of protein. In addition, organic 
solvents can replace several water molecules in the 
hydrophobic area of the protein surface and associate 
with proteins by decreasing the water concentration in 
the solution; this process causes the protein solubility to 
 
Table 1. MRM parameters for the analysis of 6-MP, 6-MMP, 6-TGMP and 5-FU 
Analyte Parent ion 
(m/z) 
Product ion 
(m/z) 
Cone 
voltage 
Collision 
energy 
Ion 
mode 
Abundance 
6-MP 153.10 126.00 44 20 ESI + 4.41 e^4 
  119.09 52 23 ESI + 4.41 e^6 
6-MMP 167.05 152.03 38 22 ESI + 2.96 e^5 
  126.03 38 18 ESI + 1.19 e^6 
6-TGMP 380.16 168.00 44 18 ESI + 4.41 e^6 
  151.10 32 50 ESI + 2.11 e^6 
5-FU 129.15 86.17 28 24 ESI - 1.21 e^3 
  42.05 28 14 ESI - 9.48 e^4 
MRM: multiple reaction monitoring; 6-MP: 6-mercaptopurine; 6-MMP: 6-methylmercaptopurine;  
6-TGMP: 6-thioguanosine-5’-monophosphate, 5-FU: 5-fluorouracil 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1. Mass spectra and ion fragmentation: (a) 6-mercaptopurine, (b) 6-methylmercaptopurine, (c) 6-thioguanosine-
5’-monophosphate and (d) 5-fluorouracil 
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Table 2. Extracts from DBS samples using various solvents and reconstitution 
Solvent Reconstitution  Area 
 (100 µL) 6-MP 6-MMP 6-TGMP 5-FU 
Methanol 100% Methanol 10% 13763 82175 423 7360 
(4 mL) Acetonitrile 10% 89747 26377 246 3407 
Methanol 90% Methanol 10% 80125 219314 3646 5970 
(1 mL) Acetonitrile 10% 87707 258755 3472 6103 
Acetonitrile 90% Methanol 10% 11488 337009 419 15121 
(1 mL) Acetonitrile 10% 90506 239771 385 13495 
 
 
Fig 2. Chromatograms of blank matrix extracted without internal standard (a) and LLOQ sample extracted with 
internal standard (b) 
 
decrease and allows for precipitation [16]. 
Three solvents, methanol 100% (v/v), methanol 
90% (v/v) and acetonitrile 90% (v/v), were compared by 
sonication for 25 min and reconstituting in methanol 10% 
(v/v) and acetonitrile 10% (v/v). The mean values of 
peak areas acquired through UPLC-MS/MS were used 
for comparison of the three extraction solvent 
efficiencies, as shown in Table 2. Generally, acetonitrile 
90% (v/v) has been used as the extraction solvent for 6-
MP, 6-MMP and 5-FU analysis with UPLC-MS/MS 
because it shows better area than methanol. Methanol 
90% (v/v) has a better extraction results for 6-TGMP. All 
the target compounds were extracted effectively by 
methanol 90% (v/v), and the differences were not large. 
Methanol 90% (v/v) showed the best extraction results 
for most of the target compounds and this solvent was 
selected for 6-MP, metabolites and IS analysis of 
blood, based on the experimental results. 
 
Bioanalytical Validation Assay 
 
Selectivity and carry-over 
Interference from endogenous compounds was 
investigated by analyzing six different sources of the 
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appropriate blank matrix. Blank whole blood was spotted 
onto DBS analysis paper and prepared using the 
preparation method detailed above. The absence of 
interfering components is considered acceptable where 
 
Table 3. Accuracy and precision data of the assay 
Nominal Within-run (n = 5) Between-run (n = 5) 
conc. Measured Bias Precision Measured Bias Precision 
(ng/mL) conc. (ng/mL) (% diff) (% CV) conc. (ng/mL) (% diff) (% CV) 
 [mean ± SD]   [mean ± SD]   
6-MP      
25.50 28.74 ± 2.36 -0.40 – 19.33 8.23 29.22 ± 1.59 4.46 – 19.94 5.43 
75.00 78.33 ± 6.47 -1.02 – 13.65 6.61 78.45 ± 1.33 9.66 – 13.12 1.30 
510.00 575.74 ± 14.40 7.92 – 14.92 2.5 530.57 ± 33.47 -4.26 – 10.96 6.31 
918.00 943.80 ± 65.35 -8.01 – 10.50 6.92 827.73 ± 51.14 -14.76 –1.315 6.18 
6-MMP      
25.50 28.19 ± 2.01 -2.23 – 16.69 7.11 29.32 ± 0.72 11.94 – 18.54 2.44 
75.00 82.72 ± 0.48 13.15 – 14.44 0.46 81.23 ± 1.93 7.93 – 12.18 1.91 
510.00 541.98 ± 48.75 -7.02 – 13.49 8.99 527.36 ± 55.59 -10.3 – 14.16 10.54 
918.00 1025.26 ± 43.13 3.40 – 15.00 4.21 947.51 ± 37.35 -1.21 – 9.84 3.94 
6-TGMP     
51.00 58.75 ± 0.91 12.48 – 17.19 1.54 58.34 ± 0.96 11.55 – 16.69 1.64 
150.00 161.11 ± 6.19 5.37 – 14.42 3.13 153.84 ± 7.65 4.41 – 14.56 3.83 
510.00 464.83 ± 22.58 -12.61 – 1.56 4.86 508.00 ± 39.59 -9.87 – 9.14 7.79 
918.00 800.57 ± 6.40 -13.33 – 11.6 0.80 956.78 ± 44.58 -1.88 – 8.36 4.66 
6-MP: 6-mercaptopurine; 6-MMP:6-methylmercaptopurine; 6-TGMP: 6-thioguanosine-5’-monophosphate 
 
Table 4. Matrix effect: analytes and internal standard 
Concentration 
(ng/mL) 
Blood lot ME (%) 
6-MP 6-MMP 6-TGMP 5-FU 
QCL 
6-MP and 6-MMP = 
75.00 
6-TGMP = 150.00 
A 69.57 83.91 90.24 82.00 
 69.85 81.94 87.57 78.15 
B 83.43 79.19 97.20 80.65 
 79.76 85.51 92.54 81.80 
C 83.46 83.83 85.77 83.15 
 79.97 77.76 78.06 81.47 
D 78.61 97.67 87.57 82.64 
 73.41 93.87 86.26 80.82 
E 80.67 96.58 75.39 80.67 
 100.10 96.73 74.46 79.80 
F 90.09 83.14 88.69 82.72 
 80.39 91.57 88.44 82.43 
QCH = 918.00 
A 76.66 91.31 89.48 82.10 
 70.70 83.31 89.71 78.71 
B 70.64 80.39 98.69 80.63 
 75.02 83.65 89.11 83.05 
C 66.94 88.51 82.66 80.27 
 72.29 70.06 87.84 78.25 
D 63.58 80.58 73.52 78.89 
 81.40 82.33 77.47 79.66 
E 67.13 73.46 73.89 81.26 
 73.50 92.66 73.74 83.49 
F 85.24 85.18 89.89 81.50 
 81.60 83.12 86.35 76.06 
Measured 
QCL 80.78 87.64 86.01 81.35 
QCH 73.73 82.88 84.36 80.32 
SD 
QCL 8.42 7.21 6.83 1.43 
QCH 6.59 6.53 8.09 2.14 
% CV 
QCL 10.42 8.23 7.94 1.76 
QCH 8.93 7.88 9.59 2.67 
ME: matrix effect; QCL: quality control low; QCH: quality control high: 6-MP: 6-mercaptopurine; 6-MMP:6-
methylmercaptopurine; 6-TGMP: 6-thioguanosine-5’-monophosphate 
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the response is less than 20% of the lower limit of 
quantification (LLOQ) for the analyte. Interference may 
be caused by substances with equal mass, and with the 
same retention times as the analytes. The optimized 
methods were selective for 6-MP, 6-MMP, 6-TGMP and 
5-FU because the response of blank matrix is less than 
20% of LLOQ analyte [15]. Corresponding 
chromatograms are presented in Fig. 2. 
Carry-over was assessed by injecting blank DBS 
samples following a high-concentration sample of 
calibration standard at the upper limit of quantification. 
Carry-over in the blank should not be greater than 20% 
of the LLOQ. Carry-over was avoided, and the analyte 
signal at LLOQ concentration substantially exceeded the 
minimal limit of the validation requirements. The 
analytical concentration of 1020 ng/mL gave a 6-MP 
carry-over yield of 4.30–7.46%, 6-MMP of 0–5.17% and 
6-TGMP of 5.33–13.46%. 
 
Linearity 
Calibration curves were measured using a blank, a 
zero and samples at five concentration levels and 
prepared at scalar concentrations. The mean regression 
coefficient was calculated. Linearity was achieved for a 
range of 25.5 to 1020 ng/mL for 6-MP and 6-MMP, and a 
range of 51 to 1020 ng/mL for 6-TGMP. The linear 
regression of calibration curve resulted consistently in a 
correlation coefficient of r2 > 0.9940, 0.9878 and 0.9882 
for 6-MP, 6-MMP and 6-TGMP, respectively. The linear 
model test based on ANOVA showed no significant lack 
of fit. The CV and biases at each calibration level were 
all less than 15%. 
 
Accuracy and precision 
Accuracy and precision were determined at four 
concentrations stated as LLOQ quality control low 
(QCL), quality control medium (QCM) and quality control 
high (QCH). Accuracy was determined by differences 
between theoretical value and calculated value and 
expressed as the bias (% diff) while precision was 
expressed as the coefficient of variation (% CV). These 
parameters should be ≤ ± 15% for the quality control 
samples and should be ≤ 20% for LLOQ. Within-run and 
between-run precision and accuracy data were always 
less than 15% for the QC samples and less than 20% 
for the LLOQ (Table 3). 
 
Matrix effect 
Matrix effect (ME) was assessed using at least six 
blank matrices from individual donors. Matrix effects 
were determined in triplicate (n = 3) by the comparison 
of two values at low and high concentrations. The area 
value of neat standard analyzed with LC-MS/MS was 
directly expressed as A. Standard spiked into the 
extraction solvent after extraction of blood spotted on a 
DBS card was expressed as B. The matrix effect (%) 
was calculated as B/A × 100%. The matrix effect 
values of 6-MP, 6-MMP, 6-TGMP and IS were 
observed at low levels as 80.78, 87.64, 86.01 and 
81.35%, respectively. At the high levels, it showed the 
lowest matrix effect value of 73.73, 82.88, 84.36, and 
80.32%, respectively. The results indicate that ion 
suppression affected the ionization in LC-MS/MS. Ion 
suppression or enhancement within 10% indicates no 
interference affecting the ionization of the analyte [20]. 
In this analysis with DBS samples, most target 
compounds showed ion suppression values above 
10%, indicating that DBS card components had 
considerable effects on the ionization of analytes 
(Table 4). 
 
Stability 
Stability of analytes in DBS samples was 
assessed in terms of short-term stability of up to 24 h at 
room temperature and long-term stability of up to 15 
days. Stock solution stability was evaluated by 
comparing the peak areas obtained from direct 
injection of a diluted solution prepared from the stock 
stored at -20 °C for 16 days with other peak areas 
obtained from direct injection obtained from freshly 
prepared stock. The stock solution did not show 
degradation after 16 days of storage at -20 °C from 
freshly prepared stock solution. To determine long-term 
stability, the DBS samples should be stored in sealed 
plastic bags containing silica gel desiccants for 15 
days, then determined by analyzing DBS samples 
 
Table 5. Long-term stability of 6-MP, 6-MMP and 6-TGMP 
Time 
(days) 
6-MP 6-MMP 6-TGMP 
QCL  QCH  QCL QCH QCL QCH 
%CV %diff %CV %diff %CV %diff %CV %diff %CV %diff %CV %diff 
1 7.95 
-1.39 
– 
12.82 
8.93 
-7.59 
–  
8.81 
1.27 
11.69 
– 
14.50 
5.42 
2.50   
– 
13.97 
1.75 
4.03   
–   
7.69 
5.58 
-3.13 
–   
8.19 
15 1.67 
7.92   
–   
1.44 
1.86 
-9.26 
–  
6.66 
0.73 
12.44 
– 
14.08 
4.55 
-1.90 
–   
6.39 
7.06 
-1.00 
– 
13.97 
4.60 
4.43   
– 
13.80 
QCL: quality control low; QCH: quality control high: 6-MP: 6-mercaptopurine; 6-MMP:6-methylmercaptopurine; 6-TGMP: 6-thioguanosine-
5’-monophosphate 
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containing the analytes at two concentrations (QCL and 
QCH; each concentration; n = 3). Stability testing 
revealed that 6-MP, 6-MMP and 6-TGMP spotted on 
DBS cards were stable for at least 15 days if stored at 
room temperature (as shown in Table 5). 
Our method has the advantages of fast run time (5 
min) and simple sample preparation with protein 
precipitation [21]. The analytical method was valid, and 
all the parameters fulfilled the acceptance criteria of the 
EMA Bioanalytical Method Validation Guidelines. Further 
studies need to be carried out, specifically the 
application of this method to therapeutic drug monitoring 
of ALL patients receiving 6-MP as their therapy. 
 
CONCLUSION 
 
The analytical method was valid for the in vitro 
simultaneous analysis of 6-MP, 6-MMP and 6-TGMP in 
DBS samples. All the parameters fulfilled the acceptance 
criteria of the EMA Bioanalytical Method Validation 
Guidelines. The DBS preparation procedure is simple, 
involving protein precipitation followed by analyte 
reconstitution. 
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